Premarket movers: Quest, Labcorp hit by CMS cuts
U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.
How this was made
The 30-second read
Why it matters
The announcements represent the first public disclosure of the proposed fee cuts, creating material risk for companies reliant on Medicare lab payments and offering upside for firms announcing buybacks or reporting earnings beats.
Market read
The CMS proposal is a fresh regulatory development with immediate price impact on major lab service stocks, while other companies in the list react to unrelated corporate actions.
What to watch
Potential for legislative intervention or legal challenges to CMS proposals could mitigate impact.
Background
CMS released preliminary reimbursement proposals affecting Medicare lab fees, prompting immediate pre‑market moves in several listed healthcare and tech companies.
Ticker impact
Quest Diagnostics fell 6.9% in pre‑market after CMS announced proposed lab fee cuts up to 15% starting Jan 1 2027.
Further downside risk if CMS finalizes the cuts.
The proposal targets a core revenue stream; the stock already reacted sharply.
Labcorp dropped 4.5% in pre‑market after CMS released preliminary 2027 Clinical Laboratory Fee Schedule rates proposing up to 15% cuts.
Continued weakness unless CMS revises the proposal.
Labcorp’s revenue heavily depends on Medicare lab fees; the news is fresh and material.
Vicor surged nearly 9.9% after raising its Q3 2026 revenue outlook, now expecting >20% sequential growth.
Potential further rally if guidance holds.
Guidance lift is material for a small cap; market reaction already strong.
GameStop rose 3.5% after CEO Ryan Cohen disclosed a $26.4 million purchase of additional shares.
Modest upside as the market views the purchase favorably.
While insider buying is positive, the amount is modest relative to market cap.
AnaptysBio climbed 3.8% after reporting Q2 2026 revenue of $27.5 million, 36% above expectations.
Potential short‑term rally if guidance remains strong.
Revenue beat is positive but the company remains small; impact may be limited.
Market effects
Healthcare lab services face reimbursement headwinds; biotech and tech services see mixed catalysts.
U.S. pre‑market activity influenced by CMS policy proposals.
CMS changes could set precedent for other payer systems internationally.
Counterpoint
If CMS softens the cuts after stakeholder pushback, the sell‑off may be overdone.
Key entities
- RegulatorCenters for Medicare & Medicaid Services
U.S. federal agency proposing lab fee reductions.
- CompanyQuest Diagnostics
Diagnostic testing provider impacted by CMS proposal.
- CompanyLabcorp
Clinical laboratory services firm facing similar fee cuts.
